Foghorn Therapeutics Q1 EPS $(0.29), Inline, Sales $3.267M Miss $7.438M Estimate
Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.29) per share which met the analyst consensus estimate. This is a 3.33 percent increase over losses of $(0.30) per share from the same period last year.